XML 40 R32.htm IDEA: XBRL DOCUMENT
v3.25.2

Product Sales year-on-year analysis: Q2 2025 (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2025 | Jun. 30, 2024 | Jun. 30, 2025 | Jun. 30, 2024
Product sales |  |  |  |
Product Sales | $ 13,795 | $ 12,452 | $ 26,670 | $ 24,629
Actual %, year-on-year | 11.00% |  | 8.00% |
CER %, year-on-year | 10.00% |  | 10.00% |
US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 5,852 |  | $ 11,085 |
Actual %, year-on-year | 12.00% |  | 10.00% |
Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 3,705 |  | $ 7,598 |
Actual %, year-on-year | 11.00% |  | 8.00% |
CER %, year-on-year | 13.00% |  | 12.00% |
Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 2,946 |  | $ 5,568 |
Actual %, year-on-year | 12.00% |  | 8.00% |
CER %, year-on-year | 8.00% |  | 8.00% |
Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,292 |  | $ 2,419 |
Actual %, year-on-year | 4.00% |  | 2.00% |
CER %, year-on-year | 1.00% |  | 2.00% |
Total Oncology |  |  |  |
Product sales |  |  |  |
Product Sales | $ 5,854 |  | $ 11,085 |
Actual %, year-on-year | 18.00% |  | 14.00% |
CER %, year-on-year | 17.00% |  | 15.00% |
Total Oncology | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 2,770 |  | $ 5,167 |
Actual %, year-on-year | 20.00% |  | 18.00% |
Total Oncology | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,310 |  | $ 2,628 |
Actual %, year-on-year | 19.00% |  | 14.00% |
CER %, year-on-year | 22.00% |  | 19.00% |
Total Oncology | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,183 |  | $ 2,215 |
Actual %, year-on-year | 17.00% |  | 13.00% |
CER %, year-on-year | 12.00% |  | 12.00% |
Total Oncology | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 591 |  | $ 1,075 |
Actual %, year-on-year | 5.00% |  | (1.00%) |
CER %, year-on-year | 2.00% |  |  |
Tagrisso |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,810 |  | $ 3,488 |
Actual %, year-on-year | 13.00% |  | 9.00% |
CER %, year-on-year | 12.00% |  | 10.00% |
Tagrisso | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 761 |  | $ 1,439 |
Actual %, year-on-year | 16.00% |  | 12.00% |
Tagrisso | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 489 |  | $ 1,008 |
Actual %, year-on-year | 13.00% |  | 10.00% |
CER %, year-on-year | 15.00% |  | 13.00% |
Tagrisso | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 351 |  | $ 658 |
Actual %, year-on-year | 8.00% |  | 5.00% |
CER %, year-on-year | 4.00% |  | 5.00% |
Tagrisso | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 209 |  | $ 383 |
Actual %, year-on-year | 9.00% |  | 3.00% |
CER %, year-on-year | 5.00% |  | 3.00% |
Imfinzi |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,455 |  | $ 2,716 |
Actual %, year-on-year | 27.00% |  | 20.00% |
CER %, year-on-year | 26.00% |  | 21.00% |
Imfinzi | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 844 |  | $ 1,572 |
Actual %, year-on-year | 36.00% |  | 31.00% |
Imfinzi | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 152 |  | $ 294 |
Actual %, year-on-year | 31.00% |  | 20.00% |
CER %, year-on-year | 35.00% |  | 28.00% |
Imfinzi | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 285 |  | $ 537 |
Actual %, year-on-year | 26.00% |  | 17.00% |
CER %, year-on-year | 21.00% |  | 17.00% |
Imfinzi | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 174 |  | $ 313 |
Actual %, year-on-year | (5.00%) |  | (11.00%) |
CER %, year-on-year | (8.00%) |  | (11.00%) |
Calquence |  |  |  |
Product sales |  |  |  |
Product Sales | $ 872 |  | $ 1,634 |
Actual %, year-on-year | 10.00% |  | 8.00% |
CER %, year-on-year | 10.00% |  | 9.00% |
Calquence | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 583 |  | $ 1,090 |
Actual %, year-on-year | 5.00% |  | 4.00% |
Calquence | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 49 |  | $ 103 |
Actual %, year-on-year | 36.00% |  | 36.00% |
CER %, year-on-year | 43.00% |  | 49.00% |
Calquence | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 198 |  | $ 368 |
Actual %, year-on-year | 19.00% |  | 15.00% |
CER %, year-on-year | 14.00% |  | 15.00% |
Calquence | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 42 |  | $ 73 |
Actual %, year-on-year | 27.00% |  | 12.00% |
CER %, year-on-year | 28.00% |  | 15.00% |
Lynparza |  |  |  |
Product sales |  |  |  |
Product Sales | $ 838 |  | $ 1,564 |
Actual %, year-on-year | 13.00% |  | 8.00% |
CER %, year-on-year | 11.00% |  | 9.00% |
Lynparza | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 378 |  | $ 689 |
Actual %, year-on-year | 18.00% |  | 14.00% |
Lynparza | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 162 |  | $ 323 |
Actual %, year-on-year | 6.00% |  | 1.00% |
CER %, year-on-year | 7.00% |  | 4.00% |
Lynparza | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 229 |  | $ 425 |
Actual %, year-on-year | 11.00% |  | 7.00% |
CER %, year-on-year | 7.00% |  | 6.00% |
Lynparza | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 69 |  | $ 127 |
Actual %, year-on-year | 5.00% |  | 1.00% |
CER %, year-on-year | 2.00% |  | 2.00% |
Enhertu |  |  |  |
Product sales |  |  |  |
Product Sales | $ 230 |  | $ 428 |
Actual %, year-on-year | 81.00% |  | 72.00% |
CER %, year-on-year | 82.00% |  | 76.00% |
Enhertu | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 156 |  | $ 292 |
Actual %, year-on-year |  |  | 82.00% |
CER %, year-on-year |  |  | 88.00% |
Enhertu | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 51 |  | $ 94 |
Actual %, year-on-year | 63.00% |  | 65.00% |
CER %, year-on-year | 56.00% |  | 63.00% |
Enhertu | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 23 |  | $ 42 |
Actual %, year-on-year | 24.00% |  | 35.00% |
CER %, year-on-year | 28.00% |  | 41.00% |
Zoladex |  |  |  |
Product sales |  |  |  |
Product Sales | $ 284 |  | $ 567 |
Actual %, year-on-year | 4.00% |  | 3.00% |
CER %, year-on-year | 5.00% |  | 6.00% |
Zoladex | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 4 |  | $ 9 |
Actual %, year-on-year | (8.00%) |  | 16.00% |
Zoladex | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 219 |  | $ 442 |
Actual %, year-on-year | 9.00% |  | 7.00% |
CER %, year-on-year | 11.00% |  | 10.00% |
Zoladex | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 38 |  | $ 72 |
Actual %, year-on-year | (9.00%) |  | (7.00%) |
CER %, year-on-year | (13.00%) |  | (8.00%) |
Zoladex | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 23 |  | $ 44 |
Actual %, year-on-year | (9.00%) |  | (10.00%) |
CER %, year-on-year | (11.00%) |  | (9.00%) |
Truqap |  |  |  |
Product sales |  |  |  |
Product Sales | $ 170 |  | $ 302 |
Actual %, year-on-year | 84.00% |  |  |
CER %, year-on-year | 84.00% |  |  |
Truqap | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 142 |  | $ 253 |
Actual %, year-on-year | 57.00% |  | 80.00% |
Truqap | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 6 |  | $ 8 |
Truqap | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | 14 |  | 28 |
Truqap | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | 8 |  | 13 |
Imjudo |  |  |  |
Product sales |  |  |  |
Product Sales | $ 89 |  | $ 170 |
Actual %, year-on-year | 20.00% |  | 25.00% |
CER %, year-on-year | 18.00% |  | 25.00% |
Imjudo | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 57 |  | $ 111 |
Actual %, year-on-year | 17.00% |  | 26.00% |
Imjudo | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 7 |  | $ 12 |
Actual %, year-on-year | 93.00% |  | 58.00% |
CER %, year-on-year | 84.00% |  | 68.00% |
Imjudo | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 12 |  | $ 23 |
Actual %, year-on-year | 39.00% |  | 43.00% |
CER %, year-on-year | 35.00% |  | 43.00% |
Imjudo | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 13 |  | $ 24 |
Actual %, year-on-year |  |  | (1.00%) |
CER %, year-on-year | (4.00%) |  | (2.00%) |
Oncology, Others |  |  |  |
Product sales |  |  |  |
Product Sales | $ 106 |  | $ 216 |
Actual %, year-on-year | (12.00%) |  | (10.00%) |
CER %, year-on-year | (13.00%) |  | (8.00%) |
Oncology, Others | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1 |  | $ 4 |
Actual %, year-on-year | (76.00%) |  | (63.00%) |
Oncology, Others | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 70 |  | $ 146 |
Actual %, year-on-year | (11.00%) |  | (7.00%) |
CER %, year-on-year | (10.00%) |  | (5.00%) |
Oncology, Others | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 5 |  | $ 10 |
Actual %, year-on-year | (27.00%) |  | (16.00%) |
CER %, year-on-year | (30.00%) |  | (16.00%) |
Oncology, Others | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 30 |  | $ 56 |
Actual %, year-on-year |  |  | (6.00%) |
CER %, year-on-year | (5.00%) |  | (7.00%) |
BioPharmaceuticals: total CVRM |  |  |  |
Product sales |  |  |  |
Product Sales | $ 3,261 |  | $ 6,505 |
Actual %, year-on-year | 3.00% |  | 6.00% |
CER %, year-on-year | 3.00% |  | 7.00% |
BioPharmaceuticals: total CVRM | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 665 |  | $ 1,351 |
Actual %, year-on-year | (10.00%) |  | (9.00%) |
BioPharmaceuticals: total CVRM | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,512 |  | $ 3,064 |
Actual %, year-on-year | 9.00% |  | 11.00% |
CER %, year-on-year | 11.00% |  | 15.00% |
BioPharmaceuticals: total CVRM | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 889 |  | $ 1,696 |
Actual %, year-on-year | 5.00% |  | 9.00% |
CER %, year-on-year | 1.00% |  | 9.00% |
BioPharmaceuticals: total CVRM | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 195 |  | $ 394 |
Actual %, year-on-year | 2.00% |  | 6.00% |
CER %, year-on-year | (2.00%) |  | 6.00% |
Farxiga |  |  |  |
Product sales |  |  |  |
Product Sales | $ 2,150 |  | $ 4,206 |
Actual %, year-on-year | 11.00% |  | 11.00% |
CER %, year-on-year | 10.00% |  | 13.00% |
Farxiga | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 420 |  | $ 803 |
Actual %, year-on-year | 6.00% |  | (7.00%) |
Farxiga | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 859 |  | $ 1,730 |
Actual %, year-on-year | 13.00% |  | 17.00% |
CER %, year-on-year | 15.00% |  | 23.00% |
Farxiga | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 765 |  | $ 1,448 |
Actual %, year-on-year | 13.00% |  | 17.00% |
CER %, year-on-year | 8.00% |  | 17.00% |
Farxiga | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 106 |  | $ 225 |
Actual %, year-on-year | 3.00% |  | 7.00% |
CER %, year-on-year | (1.00%) |  | 7.00% |
Crestor |  |  |  |
Product sales |  |  |  |
Product Sales | $ 319 |  | $ 635 |
Actual %, year-on-year | 9.00% |  | 8.00% |
CER %, year-on-year | 9.00% |  | 10.00% |
Crestor | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 12 |  | $ 24 |
Actual %, year-on-year | 3.00% |  | 11.00% |
Crestor | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 275 |  | $ 547 |
Actual %, year-on-year | 17.00% |  | 15.00% |
CER %, year-on-year | 18.00% |  | 17.00% |
Crestor | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 32 |  | $ 64 |
Actual %, year-on-year | (10.00%) |  | (9.00%) |
CER %, year-on-year | (13.00%) |  | (8.00%) |
Brilinta |  |  |  |
Product sales |  |  |  |
Product Sales | $ 215 |  | $ 520 |
Actual %, year-on-year | (37.00%) |  | (22.00%) |
CER %, year-on-year | (38.00%) |  | (21.00%) |
Brilinta | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 99 |  | $ 271 |
Actual %, year-on-year | (48.00%) |  | (23.00%) |
Brilinta | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 63 |  | $ 137 |
Actual %, year-on-year | (20.00%) |  | (18.00%) |
CER %, year-on-year | (20.00%) |  | (16.00%) |
Brilinta | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 51 |  | $ 107 |
Actual %, year-on-year | (26.00%) |  | (21.00%) |
CER %, year-on-year | (29.00%) |  | (21.00%) |
Brilinta | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 2 |  | $ 5 |
Actual %, year-on-year | (46.00%) |  | (39.00%) |
CER %, year-on-year | (39.00%) |  | (34.00%) |
Seloken |  |  |  |
Product sales |  |  |  |
Product Sales | $ 148 |  | $ 308 |
Actual %, year-on-year | (2.00%) |  | (2.00%) |
CER %, year-on-year | 1.00% |  | 2.00% |
Seloken | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 143 |  | $ 298 |
Actual %, year-on-year | (2.00%) |  | (3.00%) |
CER %, year-on-year |  |  | 1.00% |
Seloken | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 4 |  | $ 8 |
Actual %, year-on-year | 4.00% |  | 34.00% |
CER %, year-on-year | 11.00% |  | 38.00% |
Seloken | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1 |  | $ 2 |
Actual %, year-on-year | (5.00%) |  | (9.00%) |
CER %, year-on-year | (3.00%) |  | (5.00%) |
Lokelma |  |  |  |
Product sales |  |  |  |
Product Sales | $ 175 |  | $ 328 |
Actual %, year-on-year | 29.00% |  | 31.00% |
CER %, year-on-year | 27.00% |  | 32.00% |
Lokelma | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 75 |  | $ 144 |
Actual %, year-on-year | 18.00% |  | 25.00% |
Lokelma | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 33 |  | $ 63 |
Actual %, year-on-year | 52.00% |  | 50.00% |
CER %, year-on-year | 54.00% |  | 54.00% |
Lokelma | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 30 |  | $ 56 |
Actual %, year-on-year | 33.00% |  | 36.00% |
CER %, year-on-year | 29.00% |  | 36.00% |
Lokelma | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 37 |  | $ 65 |
Actual %, year-on-year | 30.00% |  | 27.00% |
CER %, year-on-year | 24.00% |  | 26.00% |
roxadustat |  |  |  |
Product sales |  |  |  |
Product Sales | $ 72 |  | $ 150 |
Actual %, year-on-year | (18.00%) |  | (8.00%) |
CER %, year-on-year | (18.00%) |  | (7.00%) |
roxadustat | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 72 |  | $ 150 |
Actual %, year-on-year | (18.00%) |  | (8.00%) |
CER %, year-on-year | (18.00%) |  | (7.00%) |
Wainua |  |  |  |
Product sales |  |  |  |
Product Sales | $ 44 |  | $ 84 |
Wainua | US |  |  |  |
Product sales |  |  |  |
Product Sales | 43 |  | 82 |
Wainua | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales |  |  | 1 |
Wainua | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | 1 |  | 1 |
CVRM, Others |  |  |  |
Product sales |  |  |  |
Product Sales | $ 138 |  | $ 274 |
Actual %, year-on-year | (27.00%) |  | (27.00%) |
CER %, year-on-year | (28.00%) |  | (26.00%) |
CVRM, Others | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 16 |  | $ 27 |
Actual %, year-on-year | (73.00%) |  | (74.00%) |
CVRM, Others | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 67 |  | $ 138 |
Actual %, year-on-year | 24.00% |  | 14.00% |
CER %, year-on-year | 24.00% |  | 16.00% |
CVRM, Others | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 38 |  | $ 76 |
Actual %, year-on-year | (35.00%) |  | (37.00%) |
CER %, year-on-year | (37.00%) |  | (37.00%) |
CVRM, Others | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 17 |  | $ 33 |
Actual %, year-on-year | (8.00%) |  | 7.00% |
CER %, year-on-year | (12.00%) |  | 7.00% |
BioPharmaceuticals: total Respiratory & Immunology |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,988 |  | $ 3,935 |
Actual %, year-on-year | 11.00% |  | 9.00% |
CER %, year-on-year | 10.00% |  | 10.00% |
BioPharmaceuticals: total Respiratory & Immunology | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 977 |  | $ 1,842 |
Actual %, year-on-year | 18.00% |  | 18.00% |
BioPharmaceuticals: total Respiratory & Immunology | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 381 |  | $ 910 |
Actual %, year-on-year | (14.00%) |  | (12.00%) |
CER %, year-on-year | (13.00%) |  | (9.00%) |
BioPharmaceuticals: total Respiratory & Immunology | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 422 |  | $ 800 |
Actual %, year-on-year | 21.00% |  | 18.00% |
CER %, year-on-year | 16.00% |  | 17.00% |
BioPharmaceuticals: total Respiratory & Immunology | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 208 |  | $ 383 |
Actual %, year-on-year | 20.00% |  | 19.00% |
CER %, year-on-year | 19.00% |  | 21.00% |
Symbicort |  |  |  |
Product sales |  |  |  |
Product Sales | $ 715 |  | $ 1,438 |
Actual %, year-on-year | (1.00%) |  | (4.00%) |
CER %, year-on-year | (1.00%) |  | (2.00%) |
Symbicort | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 319 |  | $ 598 |
Actual %, year-on-year | 7.00% |  |  |
Symbicort | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 168 |  | $ 400 |
Actual %, year-on-year | (15.00%) |  | (11.00%) |
CER %, year-on-year | (14.00%) |  | (8.00%) |
Symbicort | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 137 |  | $ 272 |
Actual %, year-on-year | (5.00%) |  | (5.00%) |
CER %, year-on-year | (8.00%) |  | (5.00%) |
Symbicort | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 91 |  | $ 168 |
Actual %, year-on-year | 11.00% |  | 7.00% |
CER %, year-on-year | 11.00% |  | 10.00% |
Fasenra |  |  |  |
Product sales |  |  |  |
Product Sales | $ 502 |  | $ 920 |
Actual %, year-on-year | 19.00% |  | 18.00% |
CER %, year-on-year | 18.00% |  | 18.00% |
Fasenra | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 307 |  | $ 556 |
Actual %, year-on-year | 14.00% |  | 16.00% |
Fasenra | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 26 |  | $ 52 |
Actual %, year-on-year | 33.00% |  | 26.00% |
CER %, year-on-year | 36.00% |  | 32.00% |
Fasenra | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 125 |  | $ 229 |
Actual %, year-on-year | 27.00% |  | 19.00% |
CER %, year-on-year | 22.00% |  | 19.00% |
Fasenra | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 44 |  | $ 83 |
Actual %, year-on-year | 20.00% |  | 19.00% |
CER %, year-on-year | 18.00% |  | 20.00% |
Breztri |  |  |  |
Product sales |  |  |  |
Product Sales | $ 283 |  | $ 583 |
Actual %, year-on-year | 21.00% |  | 28.00% |
CER %, year-on-year | 20.00% |  | 29.00% |
Breztri | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 147 |  | $ 295 |
Actual %, year-on-year | 22.00% |  | 31.00% |
Breztri | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 65 |  | $ 156 |
Actual %, year-on-year | 7.00% |  | 19.00% |
CER %, year-on-year | 8.00% |  | 21.00% |
Breztri | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 46 |  | $ 87 |
Actual %, year-on-year | 32.00% |  | 34.00% |
CER %, year-on-year | 27.00% |  | 34.00% |
Breztri | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 25 |  | $ 45 |
Actual %, year-on-year | 30.00% |  | 34.00% |
CER %, year-on-year | 28.00% |  | 36.00% |
Tezspire |  |  |  |
Product sales |  |  |  |
Product Sales | $ 112 |  | $ 198 |
Actual %, year-on-year | 97.00% |  | 99.00% |
CER %, year-on-year | 91.00% |  |  |
Tezspire | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 9 |  | $ 16 |
Tezspire | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | 72 |  | 128 |
Tezspire | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 31 |  | $ 54 |
Actual %, year-on-year | 60.00% |  | 61.00% |
CER %, year-on-year | 55.00% |  | 63.00% |
Pulmicort |  |  |  |
Product sales |  |  |  |
Product Sales | $ 106 |  | $ 264 |
Actual %, year-on-year | (32.00%) |  | (30.00%) |
CER %, year-on-year | (32.00%) |  | (28.00%) |
Pulmicort | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1 |  | $ 4 |
Actual %, year-on-year | (58.00%) |  | (57.00%) |
Pulmicort | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 81 |  | $ 208 |
Actual %, year-on-year | (35.00%) |  | (34.00%) |
CER %, year-on-year | (36.00%) |  | (32.00%) |
Pulmicort | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 15 |  | $ 34 |
Actual %, year-on-year | (14.00%) |  | (8.00%) |
CER %, year-on-year | (18.00%) |  | (7.00%) |
Pulmicort | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 9 |  | $ 18 |
Actual %, year-on-year | 2.00% |  | 8.00% |
CER %, year-on-year | 2.00% |  | 11.00% |
Saphnelo |  |  |  |
Product sales |  |  |  |
Product Sales | $ 167 |  | $ 304 |
Actual %, year-on-year | 49.00% |  | 49.00% |
CER %, year-on-year | 48.00% |  | 49.00% |
Saphnelo | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 145 |  | $ 265 |
Actual %, year-on-year | 44.00% |  | 44.00% |
Saphnelo | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 4 |  | $ 7 |
Saphnelo | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | 12 |  | 21 |
Saphnelo | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 6 |  | $ 11 |
Actual %, year-on-year | 41.00% |  | 45.00% |
CER %, year-on-year | 31.00% |  | 45.00% |
Airsupra |  |  |  |
Product sales |  |  |  |
Product Sales | $ 42 |  | $ 70 |
Airsupra | US |  |  |  |
Product sales |  |  |  |
Product Sales | 42 |  | 69 |
Airsupra | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales |  |  | 1 |
Respiratory, Others |  |  |  |
Product sales |  |  |  |
Product Sales | $ 61 |  | $ 158 |
Actual %, year-on-year | (23.00%) |  | (8.00%) |
CER %, year-on-year | (24.00%) |  | (8.00%) |
Respiratory, Others | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 16 |  | $ 55 |
Actual %, year-on-year | (35.00%) |  | 4.00% |
Respiratory, Others | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 28 |  | $ 70 |
Actual %, year-on-year | (25.00%) |  | (18.00%) |
CER %, year-on-year | (25.00%) |  | (17.00%) |
Respiratory, Others | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 15 |  | $ 29 |
Actual %, year-on-year | 2.00% |  | (2.00%) |
CER %, year-on-year | (3.00%) |  | (3.00%) |
Respiratory, Others | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 2 |  | $ 4 |
Actual %, year-on-year | (8.00%) |  | (4.00%) |
CER %, year-on-year | (7.00%) |  |  |
BioPharmaceuticals: Total V&I |  |  |  |
Product sales |  |  |  |
Product Sales | $ 157 |  | $ 301 |
Actual %, year-on-year | 40.00% |  | (7.00%) |
CER %, year-on-year | 42.00% |  | (5.00%) |
BioPharmaceuticals: Total V&I | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 73 |  | $ 101 |
Actual %, year-on-year |  |  | 82.00% |
BioPharmaceuticals: Total V&I | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 38 |  | $ 121 |
Actual %, year-on-year | (6.00%) |  | (7.00%) |
CER %, year-on-year | (1.00%) |  | (3.00%) |
BioPharmaceuticals: Total V&I | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 24 |  | $ 50 |
Actual %, year-on-year |  |  | (39.00%) |
CER %, year-on-year |  |  | 37.00% |
BioPharmaceuticals: Total V&I | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 22 |  | $ 29 |
Actual %, year-on-year | (39.00%) |  | (49.00%) |
CER %, year-on-year | (40.00%) |  | (50.00%) |
Beyfortus |  |  |  |
Product sales |  |  |  |
Product Sales | $ 98 |  | $ 128 |
Beyfortus | US |  |  |  |
Product sales |  |  |  |
Product Sales | 73 |  | $ 102 |
Actual %, year-on-year |  |  | 91.00% |
Beyfortus | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | 24 |  | $ 24 |
Beyfortus | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1 |  | 2 |
Actual %, year-on-year | 34.00% |  |  |
CER %, year-on-year | 27.00% |  |  |
Synagis |  |  |  |
Product sales |  |  |  |
Product Sales | $ 49 |  | $ 162 |
Actual %, year-on-year | (39.00%) |  | (36.00%) |
CER %, year-on-year | (37.00%) |  | (33.00%) |
Synagis | US |  |  |  |
Product sales |  |  |  |
Product sales net of reversals |  |  | $ (1) |
Actual %, year-on-year |  |  | (22.00%) |
Synagis | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 38 |  | $ 121 |
Actual %, year-on-year | (7.00%) |  | (8.00%) |
CER %, year-on-year | (1.00%) |  | (3.00%) |
Synagis | Europe |  |  |  |
Product sales |  |  |  |
Product Sales |  |  | $ 25 |
Actual %, year-on-year |  |  | (62.00%) |
CER %, year-on-year |  |  | (60.00%) |
Synagis | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 11 |  | $ 17 |
Actual %, year-on-year | (68.00%) |  | (70.00%) |
CER %, year-on-year | (69.00%) |  | (71.00%) |
FluMist |  |  |  |
Product sales |  |  |  |
Product Sales | $ 10 |  | $ 10 |
Actual %, year-on-year |  |  | 20.00% |
CER %, year-on-year |  |  | 16.00% |
FluMist | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | 10 |  | $ 10 |
Total rare diseases |  |  |  |
Product sales |  |  |  |
Product Sales | $ 2,294 |  | $ 4,336 |
Actual %, year-on-year | 7.00% |  | 2.00% |
CER %, year-on-year | 7.00% |  | 3.00% |
Total rare diseases | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,346 |  | $ 2,584 |
Actual %, year-on-year | 3.00% |  | 3.00% |
Total rare diseases | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 278 |  | $ 483 |
Actual %, year-on-year | 37.00% |  | 6.00% |
CER %, year-on-year | 48.00% |  | 16.00% |
Total rare diseases | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 412 |  | $ 772 |
Actual %, year-on-year | 5.00% |  | (3.00%) |
CER %, year-on-year | 1.00% |  | (3.00%) |
Total rare diseases | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 258 |  | $ 497 |
Actual %, year-on-year | 7.00% |  | 4.00% |
CER %, year-on-year | 2.00% |  | 4.00% |
Ultomiris |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1,177 |  | $ 2,228 |
Actual %, year-on-year | 25.00% |  | 23.00% |
CER %, year-on-year | 23.00% |  | 24.00% |
Ultomiris | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 667 |  | $ 1,272 |
Actual %, year-on-year | 21.00% |  | 23.00% |
Ultomiris | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 61 |  | $ 113 |
Actual %, year-on-year | 76.00% |  | 71.00% |
CER %, year-on-year | 86.00% |  | 82.00% |
Ultomiris | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 270 |  | $ 498 |
Actual %, year-on-year | 29.00% |  | 21.00% |
CER %, year-on-year | 24.00% |  | 21.00% |
Ultomiris | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 179 |  | $ 345 |
Actual %, year-on-year | 18.00% |  | 17.00% |
CER %, year-on-year | 12.00% |  | 17.00% |
Soliris |  |  |  |
Product sales |  |  |  |
Product Sales | $ 530 |  | $ 974 |
Actual %, year-on-year | (24.00%) |  | (32.00%) |
CER %, year-on-year | (22.00%) |  | (30.00%) |
Soliris | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 280 |  | $ 568 |
Actual %, year-on-year | (30.00%) |  | (30.00%) |
Soliris | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 159 |  | $ 224 |
Actual %, year-on-year | 23.00% |  | (12.00%) |
CER %, year-on-year | 38.00% |  | (1.00%) |
Soliris | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 56 |  | $ 112 |
Actual %, year-on-year | (52.00%) |  | (57.00%) |
CER %, year-on-year | (54.00%) |  | (57.00%) |
Soliris | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 35 |  | $ 70 |
Actual %, year-on-year | (37.00%) |  | (40.00%) |
CER %, year-on-year | (38.00%) |  | (38.00%) |
Strensiq |  |  |  |
Product sales |  |  |  |
Product Sales | $ 395 |  | $ 746 |
Actual %, year-on-year | 16.00% |  | 14.00% |
CER %, year-on-year | 15.00% |  | 15.00% |
Strensiq | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 319 |  | $ 584 |
Actual %, year-on-year | 12.00% |  | 10.00% |
Strensiq | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 16 |  | $ 50 |
Actual %, year-on-year | 65.00% |  | 61.00% |
CER %, year-on-year | 58.00% |  | 67.00% |
Strensiq | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 31 |  | $ 57 |
Actual %, year-on-year | 30.00% |  | 19.00% |
CER %, year-on-year | 26.00% |  | 20.00% |
Strensiq | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 29 |  | $ 55 |
Actual %, year-on-year | 27.00% |  | 24.00% |
CER %, year-on-year | 21.00% |  | 23.00% |
Koselugo |  |  |  |
Product sales |  |  |  |
Product Sales | $ 137 |  | $ 275 |
Actual %, year-on-year | 20.00% |  | 11.00% |
CER %, year-on-year | 18.00% |  | 13.00% |
Koselugo | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 52 |  | $ 106 |
Actual %, year-on-year | (5.00%) |  | 5.00% |
Koselugo | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 36 |  | $ 76 |
Actual %, year-on-year | 51.00% |  | (9.00%) |
CER %, year-on-year | 50.00% |  | (5.00%) |
Koselugo | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 37 |  | $ 71 |
Actual %, year-on-year | 42.00% |  | 58.00% |
CER %, year-on-year | 37.00% |  | 58.00% |
Koselugo | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 12 |  | $ 22 |
Actual %, year-on-year | 28.00% |  | 25.00% |
CER %, year-on-year | 22.00% |  | 25.00% |
Other Rare Disease |  |  |  |
Product sales |  |  |  |
Product Sales | $ 55 |  | $ 113 |
Actual %, year-on-year | 16.00% |  | 12.00% |
CER %, year-on-year | 14.00% |  | 14.00% |
Other Rare Disease | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 28 |  | $ 54 |
Actual %, year-on-year | 13.00% |  | 16.00% |
Other Rare Disease | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 6 |  | $ 20 |
Actual %, year-on-year | 7.00% |  | 4.00% |
CER %, year-on-year | 4.00% |  | 16.00% |
Other Rare Disease | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 18 |  | $ 34 |
Actual %, year-on-year | 20.00% |  | 12.00% |
CER %, year-on-year | 16.00% |  | 12.00% |
Other Rare Disease | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 3 |  | $ 5 |
Actual %, year-on-year | 37.00% |  | 9.00% |
CER %, year-on-year | 32.00% |  | 10.00% |
Total Other medicines |  |  |  |
Product sales |  |  |  |
Product Sales | $ 241 |  | $ 508 |
Actual %, year-on-year | (10.00%) |  | (9.00%) |
CER %, year-on-year | (9.00%) |  | (7.00%) |
Total Other medicines | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 21 |  | $ 40 |
Actual %, year-on-year | (26.00%) |  | (23.00%) |
Total Other medicines | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 186 |  | $ 392 |
Actual %, year-on-year | 4.00% |  | 2.00% |
CER %, year-on-year | 5.00% |  | 4.00% |
Total Other medicines | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 16 |  | $ 35 |
Actual %, year-on-year | (32.00%) |  | (34.00%) |
CER %, year-on-year | (38.00%) |  | (34.00%) |
Total Other medicines | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 18 |  | $ 41 |
Actual %, year-on-year | (50.00%) |  | (41.00%) |
CER %, year-on-year | (50.00%) |  | (40.00%) |
Nexium |  |  |  |
Product sales |  |  |  |
Product Sales | $ 198 |  | $ 426 |
Actual %, year-on-year | (10.00%) |  | (7.00%) |
CER %, year-on-year | (9.00%) |  | (5.00%) |
Nexium | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 18 |  | $ 37 |
Actual %, year-on-year | (30.00%) |  | (21.00%) |
Nexium | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 157 |  | $ 333 |
Actual %, year-on-year | 7.00% |  | 5.00% |
CER %, year-on-year | 9.00% |  | 8.00% |
Nexium | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 6 |  | $ 17 |
Actual %, year-on-year | (49.00%) |  | (35.00%) |
CER %, year-on-year | (55.00%) |  | (35.00%) |
Nexium | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 17 |  | $ 39 |
Actual %, year-on-year | (52.00%) |  | (43.00%) |
CER %, year-on-year | (51.00%) |  | (41.00%) |
Other, Others |  |  |  |
Product sales |  |  |  |
Product Sales | $ 43 |  | $ 82 |
Actual %, year-on-year | (10.00%) |  | (19.00%) |
CER %, year-on-year | (11.00%) |  | (18.00%) |
Other, Others | US |  |  |  |
Product sales |  |  |  |
Product Sales | $ 3 |  | $ 3 |
Actual %, year-on-year | 12.00% |  | (46.00%) |
Other, Others | Emerging Markets |  |  |  |
Product sales |  |  |  |
Product Sales | $ 29 |  | $ 59 |
Actual %, year-on-year | (12.00%) |  | (12.00%) |
CER %, year-on-year | (11.00%) |  | (11.00%) |
Other, Others | Europe |  |  |  |
Product sales |  |  |  |
Product Sales | $ 10 |  | $ 18 |
Actual %, year-on-year | (12.00%) |  | (32.00%) |
CER %, year-on-year | (18.00%) |  | (33.00%) |
Other, Others | Established ROW |  |  |  |
Product sales |  |  |  |
Product Sales | $ 1 |  | $ 2 |
Actual %, year-on-year | 4.00% |  | 8.00% |
CER %, year-on-year | (3.00%) |  | 7.00% |

X
- Definition Represents the increase (decrease) in revenue based on constant exchange rate, year-on-year, as a percent. + References No definition available. + Details
Name: | azn_IncreaseDecreaseInRevenueConstantExchangeRateYearOnYearAsPercentage
Namespace Prefix: | azn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the actual increase (decrease) in revenue, year-on-year, as a percent. + References No definition available. + Details
Name: | azn_IncreaseDecreaseInRevenueYearOnYearPercentage
Namespace Prefix: | azn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue from sale of goods net of reversals + References No definition available. + Details
Name: | azn_RevenueFromSaleOfGoodsNetOfReversals
Namespace Prefix: | azn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_MarketsOfCustomersAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MarketsOfCustomersAxis=azn_EmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MarketsOfCustomersAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_MarketsOfCustomersAxis=azn_EstablishedRowMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TagrissoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ImfinziMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CalquenceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_LynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_EnhertuMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ZoladexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TruqapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_ImjudoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherOncologyProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CardiovascularRenalAndMetabolismProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FarxigaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_CrestorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BrilintaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SelokenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_LokelmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_RoxadustatMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_WainuaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherCardiovascularRenalAndMetabolismProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_RespiratoryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SymbicortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FasenraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BreztriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_TezspireMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_PulmicortMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SaphneloMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_AirsupraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherRespiratoryProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_VaccineAndInfectionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_BeyfortusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SynagisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_FlumistMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_RareDiseasesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_UltomirisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_SolirisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_StrensiqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_KoselugoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_RareDiseaseOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_NexiumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=azn_OtherProductsOthersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |